Early, Late-Stage, and Metastatic Prostate Cancer Treatment

Targeted Prostate Cancer Treatment Options to Help Patients Outperform Standardized Treatment Models

An early diagnosis and subsequent prostate gland removal may not be enough to prevent the cancer from recurring as an advanced prostate cancer, a few months or years later. At Envita Medical Centers, a world-class integrative center for Precision Oncology, we have been treating late-stage and complicated cancers for over 20 years using the latest in medical research and technology to give our patients a greater chance to respond to care.

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

Our revolutionary new treatments provide alternatives to invasive surgeries which can be damaging to the immune system and potentially lead to further cancer spread. Envita’s powerful and personalized combinations of leading-edge conventional treatments and advanced natural therapies have proved beneficial for patients of all stages of disease. Even those with stage IV metastatic castration-resistant prostate cancer (mCRPC) or those who had been sent to hospice by other well-established cancer centers have benefitted from our treatments and are leading healthy, disease-free lives today.

Drastic Reduction in PSA (Prostate Specific Antigen) levels and Other Significant Improvements in a Stage 4 Prostate Cancer Patient, Who Sought Precision Oncology Treatment at Envita.

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

You may ask yourself, “How can Envita be so successful where these highly regarded centers have failed?”

The answer is simple, our personalized precision oncology approach attempts to overcome treatment challenges caused by standard medicine. The standard approach does not properly account for continuing genetic mutations in cancer, which is why early treatments can be incomplete causing the cancer to spread to nearby lymph nodes and other distant parts of the body as well.

Cancer is a disease of genetic mutations, messaging, and immunity, not of tissue or tumor type and staging patterns. Genetics vary from person to person, which highlights the need for personalization in cancer care.
Dr. Dino Prato NMD
Founder/CEO Envita Medical Centers

In our clinical experience, the lack of a personalized treatment plan can make many patients experience disease relapse or metastasis, after a temporary remission when pursuing standardized treatments.

Learn more about metastasis

Personalized Precision Oncology Helps Overcome Standard Treatment Challenges

Treatment of prostate cancer can be challenging because the standard NCCN (National Comprehensive Cancer Network) guideline protocols may involve a risk of undertreatment or overtreatment, which can have devastating effects. Almost all major cancer institutions follow the NCCN guidelines to treat prostate cancer, based on its staging, which depends upon certain factors such as the PSA (Prostate Specific Antigen) levels, Gleason score, and extent of spread. These factors help in categorizing patients into low, intermediate, or high-risk groups which determine whether they need active surveillance or aggressive treatment.

However, in our clinical opinion, analyzing these factors alone may not be an accurate guide to precision-targeted treatments. The absence of precision-targeted treatments in standard treatment protocols can lead to metastatic disease, despite early diagnosis and prostate gland removal via surgeries like radical prostatectomy. Though the prostate is removed, the micro metastatic cancer cells may be sitting dormant in your blood stream for years before manifesting with symptoms, such as bone pain, back pain, blood in urine, and elevated PSA levels.

PSA test tube

According to the American Cancer Society, which relies on data compiled and maintained by the National Cancer Institute (NCI), prostate cancer is the second leading cause of cancer death in American men, due to these challenges in standard cancer care regimens.

Prostate cancer survival rates drop dramatically if the cancer metastasizes, pointing to the need for precision-targeted treatments to decrease the chances of cancer spread. Medical studies show how various chemotherapeutic drugs and radiation therapies may allow aggressive prostate cancer cells to gain advantageous mutations rendering them resistant to treatment.

The following reasons explain why and how Envita’s Personalized Precision Oncology may help in overcoming standard treatment challenges:

The NCCN guidelines do not allow access to precision oncology for all patients, but at Envita, with our unique and personalized precision approach, we aim to identify early signs of micro metastases and proactively treat the cancer even before it manifests symptoms.
Personalized precision oncology improves the chances of response in late-stage prostate cancer patients, while in early-stage, it helps reduce the likelihood of subsequent recurrence or metastasis.
The one-size-fits-all protocols are derived from large sample clinical trials, which is why they may be effective for some, but not all prostate cancer patients, despite having the same type and stage of the disease.
These standard treatment protocols may not be enough to target all the distinct cancer expressions of each individual patient, leading to a recurrence or metastatic spread of the disease as the cancer turns resistant to treatment.

Envita Medical Centers
Medical Team

Physicians with MD, MD(h), and NMD medical licenses, including certified oncologists, and certified interventional radiologists, striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+

How and Why Does Cancer Become Resistant to Standard Treatment?

Prostate cancer becomes resistant to treatment when patients fail to respond to hormone therapy, radiation, and multiple rounds of untargeted chemotherapy. In certain cases, these maximum therapeutic doses of untargeted chemo inundate the cancer cells, triggering their ability to pump out some of the anti-cancer medicines. Chemotherapeutic drug resistance lowers the cancer cells’ medicine intake capabilities, rendering treatment ineffective. High doses of untargeted chemotherapy not only trigger aggressive mutations, but they can also weaken the overall immune system, further debilitating the body’s ability to fight cancer. Approximately 90% of cancer deaths in patients are linked to chemotherapeutic drug resistance, and this is the first thing we work to overcome with Envita’s unique algorithm.

Cancer Cell Pumping Out Untargeted Chemotherapy Drugs

Cancer Cell Pumping Out Untargeted Chemotherapy Drugs

Learn more about Chemotherapeutic Drug Resistance

Envita’s Unique New Treatments for Prostate Cancer

To reduce chances of recurrence or metastasis, Envita personalizes a unique medical blueprint for each individual patient based on the N of 1 model of treatment, which allows us to modify the course of treatment as needed for mitigating risks of undertreatment or overtreatment, leading to optimum results.

Medical studies show overtreatment and undertreatment are clinical challenges in prostate cancer treatment. Overtreatment creates an unnecessary burden for many patients causing other health complications due to medicine toxicity, while undertreatment remains a common problem leading to recurrence or metastasis.

In our clinical opinion, the standardized approach to prostate cancer is limited to managing the disease, without progressing towards long-term results of a holistic recovery. To counter this nearsighted approach, Envita focuses on a four-pillared personalized precision oncology treatment algorithm, with the goal of improving patients’ quality of life, increasing longevity, and reducing toxicity.

Graph depicting Envita Medical Centers' method

Step 1

Genomic Identification Dives Deep Into Your Specific Cancer

A key factor in prostate cancer treatment includes diving deep into your specific cancer to treat the causes driving the disease, an often-ignored facet in standard NCCN guideline treatments. The majority of the patients following these one-size-fits-all protocols do not get access to genomic testing, which is a part of precision oncology.

At Envita, Every Patient’s Entire Treatment Plan Is Based on Our Detailed Precision Algorithms!

Envita Medical Centers building

Less than 20% of cancer patients get access to precision oncology, and the limited few who do get precision care, receive a watered-down version of Envita’s detailed precision algorithm. At Envita, we not only run in-depth genomic testing for all our patients, but our detailed precision algorithm analyses many more parameters than standard oncology precision testing to identify and treat each patient’s unique cancer drivers.

Envita’s Detailed Precision Algorithm Decodes Patient-Specific Cancer Drivers to Help in the Journey Towards Remission.

Envita Precision Algorithm vs.
Standard Oncology Precision Testing

RNA Transcriptome Genes
Envita Medical Centers: 20,000+
Standard Oncology: Unchecked
SNV/CNV Genes
Envita Medical Centers: 452
Standard Oncology: 309
Rearrangements/Fusion Genes
Envita Medical Centers: 51
Standard Oncology: 27
Microsatellite Instability (MSI)
Envita Medical Centers: Checked
Standard Oncology: Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers: Checked
Standard Oncology: Checked
BRCA 1/2
Envita Medical Centers: Checked
Standard Oncology: Checked
Immunohistochemistry
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Chemosensitivity
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Exosomal miRNA Analysis
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Pharmacogenomics
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Individualized Therapy Recommendation
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Inflammation Markers
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Metabolic Target Drivers
Envita Medical Centers: Checked
Standard Oncology: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Our in-depth genomic identification helps determine the genetic and epigenetic changes at the cellular and molecular level, which are directly linked to the cause and spread of each patient’s individual prostate cancer. The majority of prostate cancer patients develop bone metastases, which may be challenging to evaluate initially, but medical studies show how improving access and implementation of genomic testing will be critical to optimizing access to better therapies.

Decoding the genetic and epigenetic causes, which may be triggered by age, race, hereditary, environmental, or lifestyle factors, paves the way for a comprehensive treatment plan, designed to attack your specific prostate cancer. There has been increased reporting of certain genes, such as the BRCA genes, being connected with prostate cancer and it is estimated that men with a mutated BRCA 2 gene are seven times more likely to develop prostate cancer than the general population. Our detailed genomic overview identifies and analyses these changes and numerous other genetic mutations to treat the root cause of your prostate cancer, and aid in sustained progression against the disease.

Learn More about Genomic Analysis

Step 2

Immuno Targeting Increases Disease-Free Survival Span

Immunotherapy can be effective against prostate cancer treatment, provided they include new therapies beyond vaccine therapies and checkpoint blockades. At Envita, we have been instrumental in combining different types of advanced immunotherapies moving beyond the scope of PD-1, PD-L1, or CTLA-4 inhibitors and other smart drugs.

Advanced Immunotherapy for Prostate Cancer

Studies indicate how immunotherapy can be optimized in prostate cancer treatment with combination therapies which can change the “cold” prostate cancer tumor microenvironment to immunologically “hot” by driving T cells to the tumor, which is exactly what we are already doing here at Envita.
In our clinical opinion, including immunotherapy in early-stage cancer treatment limits chances of metastasis, because immunotherapy aims to equip your body to better tackle the cancer.
To establish actionable chemo and immuno targets, we use Envita’s Ultra Analytes Liquid Biopsy, which analyses the Circulating Tumor Cells (CTCs) free flowing in your bloodstream. CTCs are small particles of a growing tumor, which break away and enter your blood stream, spreading the cancer to other parts of your body.
Detailed investigation of these CTCs helps us examine the most recent mutations, allowing us to proactively treat the cancer in its trajectory, as opposed to treating where it has been.

Our liquid biopsy overcomes the challenges of a traditional tissue biopsy, which is invasive, difficult, and may contain outdated data, leading to poor treatment selection. Certain aggressive prostate cancers mutate fast, which is why basing your treatment on an old tissue biopsy, usually performed during initial cancer diagnosis, may be limiting in its scope.

Cryoblation on a tumor

From our experience, no clinic in the nation tests like we do, which is why we identify many more cancer biomarkers to guide treatment for your unique cancer. Biomarkers refer to the proteins, genes, and other molecules which influence your specific prostate cancer’s growth and proliferation. Precision-targeting your specific cancer biomarkers may help in effectively striking at the root of the disease.

Our unique approach to testing goes beyond establishing actionable targets, as it also provides information on toxins, infections, and other harmful agents that could be restricting treatment efficacy. This detailed data allows us to personalize your treatment, including immunotherapy options, which harness your body’s innate ability to identify and kill cancer cells.

A healthy immune system can kill thousands of cancerous and precancerous cells daily, but it is unable to execute this function when it has been weakened due to a multitude of reasons. At Envita, we intend to reactivate the immune system to suit your specific prostate cancer expressions and its ecosystem.

Learn more about our customized Immunotherapies

Step 3

Personalized Drug Design Bridges Gaps in Treatment

At Envita, your prostate cancer treatment is not limited by the scope of anti-cancer medicines available on the market, as we take personalization to the next level by custom-building medicines at our in-house pharmacy for each individual patient. Despite having the same type and stage of prostate cancer, each patient has different biomarkers, and our extensive testing helps pinpoint the medications and natural agents best suited for treating these biomarkers, which make every cancer unique.

Learn more about Personalized Drug Design
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.

In our clinical opinion, a combination of FDA approved drugs, repurposed drugs, and custom-compounded adjuvants work in tandem to attack your prostate cancer, as well as bolster your immune system. The custom compounded adjuvants include advanced phytotherapeutic drugs comprising plant extracts and herbs. You may not be aware but many of the current oncology drugs are based on phytotherapeutics, which makes plant-based drugs excellent adjuvants for cancer treatment.

At Envita, our pharmacists compound these adjuvants from scratch to suit the unique biomarkers of each individual prostate cancer patient. They also adjust the dose of FDA approved and repurposed drugs, for each individual patient, depending on their rate of metabolism. Every patient metabolizes at a different rate, making drug dosage a crucial part of cancer treatment to optimize medicine efficacy and reduce its toxicity.

Learn More about Personalized Drug Design

Step 4

Precision Deployment of New Treatments Improves Outcomes

Envita’s proprietary new treatments include targeted precision-deployment procedures for delivering customized anti-cancer medications, which not only debulk tumors, but also reactivate your immune system. The mode of precision deployment is determined based on each patient’s unique cancer expressions and the site of their tumors.

We use intravenous or interventional radiology procedures to increase the bioavailability of our customized anti-cancer medicines, enabling them to better target the cancer without impacting the surrounding healthy cells. Our medicines and procedures reduce chances of side effects such as fatigue, pain in rectum region, erectile dysfunction, or any other problems in the area of urology, commonly seen with standard hormone therapy, radiation treatments, and maximum-dose untargeted chemotherapy.

Patients may need any one or a combination of precision deployment mechanisms to effectively target their unique prostate cancer. Some of the commonly used treatments are:

Hormone Therapy also called Androgen Deprivation Therapy (ADT)

Hormone therapy is used to control the production or block the impact of male hormones, called androgens, on the prostate cancer cells. However standard hormone therapy may lead to side effects such as hot flashes, weight-gain, dizziness, and osteoporosis, often diagnosed through a bone scan. To avoid these side effects, we always use appropriate levels of immunotherapy as a follow-up to hormone therapy.

There are several types of hormone therapy to lower testosterone levels and other androgens, produced by the testicles, adrenal glands, and even the prostate cancer cells. Some of the different types of hormone therapy include:

  • Orchiectomy, which is the surgical removal of testicles
  • Luteinizing hormone releasing hormone (LHRH) agonists and antagonists
  • Anti-androgens or androgen receptor antagonists

We also use different proprietary procedures to heal your bones and relieve you from pain, in case your bone density is affected by hormone therapy prior to starting treatment at Envita.

CIPI™ (Chemo Immuno Precision Injections)

CIPI™ is our proprietary interventional radiology procedure, designed to target inoperable and fibrous tumors, deactivate them, and produce a full body systemic effect with the goal of remission. As part of this procedure, genetically targeted chemo and immuno agents are directly deployed to the tumor site via a tiny catheter, thinner than a strand of hair. Direct deployment enhances medicine impact and seals the tumor’s blood supply with radionuclide beads, destroying it and triggering antigen release which trains your immune system to identify and kill cancer elsewhere in the body.

Cryoblation on a tumor

This unique form of tumor chemoembolization goes beyond standard targeted therapies, chemotherapies, or radiation therapies because it uses genetically typed anti-cancer medicines, which are likely to be most effective for your specific prostate cancer. It produces minimal side effects as the powerful dose of customized medications are deployed directly to the tumor, reducing chances of damage to the adjoining healthy cells. CIPI™ has the potential to revolutionize the treatment of late-stage prostate cancer by treating common sites of metastasis, including bone, kidney, pancreas, spleen, or any other organ.

Envita's CIPI™ vs.
Standard Surgery

Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical incisions.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op complications.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a medically induced coma to perform an invasive surgery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other metastatic cancer sites in the body.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of hospital stays for recovery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about CIPI™

GTFC™ (Genetically Targeted Fractionated Chemotherapy)

GTFC™ is our form of low dose chemotherapy which increases the mechanisms of action against your unique prostate cancer cells, while potentially decreasing medication related side-effects. The findings of your detailed genomic analysis take the guesswork out of your treatment as it guides us to the chemo drugs with the highest potential of response to your specific prostate cancer biomarkers. This information shapes a precision-targeted treatment procedure, which combines customized immuno agents to optimize benefits for the patient.

Envita's GTFC™ vs.
Standard Chemotherapy

Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose chemo.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer mutations.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about GTFC™

Call Us Today

Our expert medical team comprising oncologists, interventional radiologists, researchers, and pharmacists, collaborate to offer a different approach to your prostate cancer treatment. They have undergone extensive training to adapt to our unique personalized precision oncology approach. We combine the latest in research-based naturopathic and conventional treatment options from around the world, not just the United States. If you or a loved one is suffering from prostate cancer or any other form of cancer, please contact us at: 866-830-4576. May God bless you on your journey to healing.

Choose Envita Medical Centers

Our team is ready to help you get your life back! Please enter your contact information and a Patient Care Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576 .

Please fill out your first name.
Please fill out your last name.
Please fill out your phone number.
Please fill out your email address.
Please make a selection.
Please make a selection.
You may request a call back from 8am-5pm Pacific Time. We cannot guarantee that you will receive a callback during your requested time, but we will do our best to contact you as soon as possible.
Please make a selection.
Please make a selection.
Please make a selection.
Max. 1000 characters. Do not include any web urls.
Please fill out your inquiry.